These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38971910)

  • 21. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
    Meroni M; Longo M; Dongiovanni P
    Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting adipose tissue inflammation to treat the underlying basis of the metabolic complications of obesity.
    Goran MI; Alderete TL
    Nestle Nutr Inst Workshop Ser; 2012; 73():49-60; discussion p61-6. PubMed ID: 23128765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT1 and Autophagy: Implications in Endocrine Disorders.
    Kim JY; Mondaca-Ruff D; Singh S; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():930919. PubMed ID: 35909524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.
    Kim SJ; Hyun J
    Mol Cells; 2024 Feb; 47(2):100010. PubMed ID: 38237744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 2 diabetes is associated with suppression of autophagy and lipid accumulation in β-cells.
    Ji J; Petropavlovskaia M; Khatchadourian A; Patapas J; Makhlin J; Rosenberg L; Maysinger D
    J Cell Mol Med; 2019 Apr; 23(4):2890-2900. PubMed ID: 30710421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of autophagy in the progression from obesity to diabetes and in the control of energy balance.
    Quan W; Jung HS; Lee MS
    Arch Pharm Res; 2013 Feb; 36(2):223-9. PubMed ID: 23371805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
    Al-Ozairi E; Irshad M; AlKandari J; Mashankar A; Alroudhan D; le Roux CW
    Diabetes Obes Metab; 2024 Sep; 26(9):4052-4059. PubMed ID: 38984381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagy in adipose tissue of patients with obesity and type 2 diabetes.
    Kosacka J; Kern M; Klöting N; Paeschke S; Rudich A; Haim Y; Gericke M; Serke H; Stumvoll M; Bechmann I; Nowicki M; Blüher M
    Mol Cell Endocrinol; 2015 Jul; 409():21-32. PubMed ID: 25818883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attenuated mTOR signaling and enhanced autophagy in adipocytes from obese patients with type 2 diabetes.
    Ost A; Svensson K; Ruishalme I; Brännmark C; Franck N; Krook H; Sandström P; Kjolhede P; Strålfors P
    Mol Med; 2010; 16(7-8):235-46. PubMed ID: 20386866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy and hepatic lipid metabolism: mechanistic insight and therapeutic potential for MASLD.
    Raza S; Rajak S; Yen PM; Sinha RA
    NPJ Metab Health Dis; 2024; 2(1):19. PubMed ID: 39100919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Polyzos SA; Targher G
    Curr Obes Rep; 2024 Jun; 13(2):242-255. PubMed ID: 38459229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.
    Abdelnabi MN; Hassan GS; Shoukry NH
    Front Immunol; 2024; 15():1437046. PubMed ID: 39156888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.